Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE: TFX) released its Q2 2024 financial results with GAAP revenue at $749.7 million, a 0.9% YoY increase. Adjusted revenue, excluding Italian payback measures, rose 2.7% to $763.5 million, up 3.4% on a constant currency basis.
GAAP diluted EPS from continuing operations decreased to $1.69, down from $2.35 in the prior year. Adjusted diluted EPS remained steady at $3.42.
Teleflex has raised its 2024 GAAP revenue growth guidance to 3.40%-4.40% and adjusted constant currency revenue growth to 4.25%-5.25%. However, it lowered its GAAP EPS guidance to $6.43-$6.83 while increasing adjusted EPS guidance to $13.80-$14.20.
The company announced a $500 million share repurchase, including a $200 million accelerated buyback. Segment highlights include a 5.6% rise in OEM revenue and a 13.1% increase in Interventional revenue. Cash reserves stand at $238.6 million, up from $222.8 million at the end of 2023.
Teleflex Incorporated (NYSE: TFX) has received FDA 510(k) clearance for its Ringer™ Perfusion Balloon Catheter (PBC), the only commercially available Percutaneous Transluminal Coronary Angioplasty (PTCA) perfusion balloon. This innovative device features a unique helical balloon that allows for continuous coronary blood flow during prolonged inflations. The Ringer™ PBC is indicated for balloon dilatation of coronary artery or bypass graft stenoses where distal blood perfusion is desired during inflation.
The Ringer PTCA Clinical Study showed that inflation of the Ringer™ PBC for 60 seconds or more was well-tolerated in most patients vulnerable to procedural ischemia. Teleflex plans a market release in August 2024, marking a significant advancement in interventional cardiology and demonstrating the company's commitment to addressing unmet clinical needs.
Teleflex Incorporated (NYSE: TFX) has secured two group purchasing agreements with Premier, Inc., effective July 1, 2024. These agreements, including the Premier National Hemostasis Products and SURPASS® Hemostasis Products agreements, offer Premier members special pricing on Teleflex's hemostatic portfolio. The SURPASS® program aims to achieve best-in-market pricing through aggregated purchasing and standardization.
Teleflex's QuikClot™ Hemostatic Dressings and Devices, which control bleeding faster than standard methods, are now available to Premier members. The portfolio includes products for various hospital departments. The agreements also cover other Teleflex hemostasis products, providing options for different bleeding scenarios in Interventional Cardiology and Radiology.
Teleflex Incorporated (NYSE: TFX) has announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit. Located in Research Triangle, North Carolina, TCAP is dedicated to reducing the spread of infections caused by multidrug-resistant organisms. The center aims to be a resource for patients, physicians, and healthcare organizations through education and partnerships with infection prevention professionals.
TCAP recently sponsored an educational webinar on healthcare-acquired infections, specifically central line-associated bloodstream infections (CLABSI). Teleflex's Arrow™ Brand of Vascular Access Products offers a comprehensive portfolio of antimicrobial Chlorhexidine catheters designed to provide broad-spectrum protection against various pathogens. The company also provides Arrow™ Maximal Barrier Kitting options to protect patients and improve procedural efficiency for clinicians.
Teleflex Incorporated (NYSE:TFX) has announced its upcoming second quarter 2024 earnings conference call, scheduled for Thursday, August 1, 2024, at 8:00 a.m. Eastern Time. The call will provide an opportunity for the company to discuss its financial results and offer an operational update. Interested parties can pre-register to receive dial-in information or access the call via a live audio webcast on the Teleflex website. An audio replay will be available from 11:00 am Eastern Time on the same day, accessible through the website or by phone using specific dial-in numbers and a conference ID.
Teleflex Incorporated (TFX) has released its 2023 Global Impact Report, showcasing achievements and outlining goals for its Corporate Social Responsibility (CSR) program. The report aligns with leading sustainability standards and emphasizes the company's commitment to social, environmental, and ethical initiatives. Key highlights include validation of net-zero greenhouse gas emissions by 2050, improved ESG ratings, renewable energy generation at manufacturing sites, and substantial research grants. The report reflects Teleflex's dedication to sustainability, stakeholder engagement, and environmental stewardship.
Teleflex Incorporated (TFX) has expanded its intraosseous vascular access portfolio with the launch of the Arrow™ EZ-IO™ Intraosseous Access Procedure Tray, the first FDA-cleared sterile, single-use IO tray in the market. This new tray includes a battery-powered driver and essential components for the IO access procedure, improving clinician workflow and patient care. The tray addresses the need for fast and precise vascular access, especially in time-critical situations where intravenous access is challenging. The development of this tray showcases Teleflex's commitment to innovation and empowering healthcare professionals.
Teleflex Incorporated presented new research findings at the American Urological Association Annual Meeting showcasing superior patient experience with the UroLift™ System for BPH. The studies demonstrated better symptom relief, quality of life improvements, and patient satisfaction compared to medication and other therapies. The UroLift™ System was found to provide rapid relief and durable outcomes with preservation of sexual function.
Teleflex Incorporated (TFX) declared a quarterly cash dividend of $0.34 per share for its common stock, payable on June 14, 2024, to shareholders of record on May 15, 2024.
Teleflex Incorporated reported first quarter financial results with revenues of $737.8 million, up 3.8% YoY, and GAAP diluted EPS of $0.33. The company lowered its GAAP revenue growth guidance to 3.35%-4.35% but raised its adjusted EPS guidance. Net revenue by segment showed growth in EMEA and OEM, while net revenue by global product category saw growth in Interventional and OEM. Other financial highlights included increases in cash, accounts receivable, and inventories. The company's outlook for 2024 includes lower revenue growth on a GAAP basis but higher diluted EPS. Non-GAAP financial measures were used to assess performance, with adjustments made for restructuring, acquisition, and integration expenses.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
